NAD+ · Research brief

5-Amino-1MQ for Cutting Cycle — Fat Loss Mechanism Explained

Real Peptides Research TeamEditorial

Updated September 24, 20269 min read

52 WORDS

Short answer

Key takeaways

5-amino-1MQ inhibits NNMT, the enzyme that depletes NAD+ during prolonged caloric restriction, restoring adipose tissue NAD+ levels by 40–60% within 10 days.
NAD+ preservation activates SIRT1 and AMPK pathways, increasing mitochondrial biogenesis and shifting cellular metabolism toward fat oxidation rather than energy conservation.
Preclinical research demonstrated 15–30% increases in energy expenditure and 30% reductions in fat mass over 10 weeks without changes in food intake or activity levels.
Human-equivalent dosing derived from rodent models suggests a range of 4–8mg/kg daily (360–720mg for a 90kg individual), though most anecdotal protocols use 50–100mg subcutaneously.
Starting 5-amino-1MQ 1–2 weeks before a deficit allows metabolic machinery to be in place before restriction begins, maximising the compound's anti-adaptation effects during the cut.

Most cutting cycles fail at week 8. Not because training intensity dropped or protein intake slipped. But because the metabolic machinery slows down faster than the caloric deficit can compensate. Enter 5-amino-1MQ: a selective NNMT (nicotinamide N-methyltransferase) inhibitor that addresses the exact enzyme responsible for declining NAD+ availability during prolonged energy restriction. Research conducted at the Pennington Biomedical Research Center found that NNMT inhibition restored NAD+ levels by 40–60% in adipose tissue within 10 days, triggering a cascade of metabolic shifts that reversed diet-induced suppression of fat oxidation. This isn't a stimulant. It's not a thyroid modulator. It works upstream. At the point where your cells decide whether to oxidise stored triglycerides or downregulate thermogenesis to conserve energy.

We've worked with athletes and researchers navigating this exact metabolic bottleneck. The gap between reading about NNMT inhibition and implementing it correctly comes down to timing, dosing precision, and understanding what 5-amino-1MQ does and doesn't do during a cut.

What is 5-amino-1MQ and how does it support cutting cycles?

5-amino-1MQ is a small-molecule NNMT inhibitor that prevents the enzyme nicotinamide N-methyltransferase from converting nicotinamide (vitamin B3) into N1-methylnicotinamide, thereby preserving NAD+ (nicotinamide adenine dinucleotide) availability in cells. During caloric restriction, NAD+ levels typically decline 20–40% as the body prioritises survival pathways over fat oxidation. 5-amino-1MQ blocks this decline, maintaining mitochondrial function and sustaining thermogenesis throughout the deficit phase. This mechanism makes it particularly valuable during cutting cycles when metabolic adaptation would otherwise reduce daily energy expenditure by 200–500 calories.

Direct Answer: Why Standard Cutting Approaches Miss the NAD+ Problem

Most cutting protocols treat metabolism as a fixed equation: calories in, calories out, adjust macros, track bodyweight. What they miss is the enzymatic shift that occurs between weeks 6 and 10 of sustained restriction. NNMT expression increases in white adipose tissue during prolonged dieting. A compensatory mechanism that depletes NAD+ to slow fat breakdown and preserve energy stores. The longer you diet, the more NNMT activity suppresses the very pathways you're trying to activate: AMPK signalling, mitochondrial biogenesis, and beta-oxidation of fatty acids. This article covers the specific mechanism by which 5-amino-1MQ for cutting cycle protocols overcomes this adaptation, the dosing frameworks supported by preclinical research, and what happens when you stack NNMT inhibition with other metabolic interventions.

The NNMT-NAD+ Axis: Why Your Mitochondria Stop Burning Fat After Week 6

NNMT is an enzyme expressed primarily in adipocytes (fat cells) and hepatocytes (liver cells). Under normal energy balance, NNMT activity remains low. During caloric restriction, however, NNMT expression upregulates 2–3× baseline levels. A protective mechanism that redirects nicotinamide away from NAD+ synthesis and into methylation pathways that signal energy conservation. The result: NAD+ levels in adipose tissue drop by 20–40%, impairing the function of NAD+-dependent enzymes like sirtuins (SIRT1, SIRT3) and PARP-1 that regulate mitochondrial efficiency and fat oxidation.

5-amino-1MQ for cutting cycle applications works by competitively inhibiting NNMT, preventing the conversion of nicotinamide to N1-methylnicotinamide. This keeps NAD+ levels elevated despite the caloric deficit. When NAD+ remains high, SIRT1 activity increases. Which deacetylates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis. More mitochondria means more capacity to oxidise fatty acids. Simultaneously, elevated NAD+ activates AMPK (AMP-activated protein kinase), the enzyme that shifts cellular metabolism from glucose storage to fat oxidation. A study published in Cell Metabolism demonstrated that NNMT inhibition in mice on a high-fat diet increased energy expenditure by 15% and reduced fat mass by 30% over 10 weeks without changes in food intake or activity levels.

Dosing, Timing, and Practical Implementation During Cutting Cycles

Preclinical research on 5-amino-1MQ used doses ranging from 25mg to 50mg per kilogram of body weight in rodent models, with the most consistent metabolic effects observed at 50mg/kg. Translating this to human-equivalent dosing using the FDA's allometric scaling factor (dividing by 6.2 for mice-to-human conversion) suggests a range of approximately 4–8mg/kg. For a 90kg individual, this equates to 360–720mg daily. Most researchers working with 5-amino-1MQ for cutting cycle protocols report anecdotal dosing in the range of 50–100mg daily administered subcutaneously, though formal human trials establishing optimal dosing have not been published as of 2026.

Timing matters. NAD+ restoration begins within 48–72 hours of NNMT inhibition, but the downstream metabolic effects. Increased mitochondrial density, upregulated fat oxidation enzyme expression. Take 7–14 days to manifest fully. Starting 5-amino-1MQ 1–2 weeks before entering a caloric deficit allows the metabolic machinery to be in place before restriction begins. Continuing throughout the cutting phase maintains NAD+ availability as NNMT expression would otherwise increase in response to sustained dieting. Discontinuing during a diet break or refeed phase allows the body to re-establish baseline NNMT activity without blunting the acute benefits of refeeding on leptin and thyroid hormone levels.

Our experience working with competitive physique athletes suggests that 5-amino-1MQ is most effective when paired with structured refeeds every 7–10 days. The compound maintains fat oxidation during deficit phases, while refeeds restore leptin signalling and prevent the thyroid suppression that typically compounds metabolic slowdown after week 8. Stacking with L-carnitine (2–3g daily) enhances fatty acid transport into mitochondria, amplifying the oxidative capacity 5-amino-1MQ unlocks.

5-Amino-1MQ for Cutting Cycle: Research Compound Comparison

Compound	Primary Mechanism	NAD+ Impact	Fat Oxidation Increase (Preclinical)	Metabolic Adaptation Mitigation	Professional Assessment
5-Amino-1MQ	NNMT inhibition → NAD+ preservation	Restores adipose NAD+ by 40–60% within 10 days	15–30% increase in energy expenditure (Cell Metabolism study)	High. Directly counteracts diet-induced NNMT upregulation	Most mechanistically targeted for sustained deficit phases. Addresses the root cause of metabolic slowdown rather than compensating downstream
GW501516 (Cardarine)	PPARδ agonist → fatty acid oxidation pathway activation	No direct NAD+ effect	20–35% shift toward fat as fuel substrate (preclinical models)	Moderate. Increases oxidation capacity but doesn't prevent adaptation	Effective for substrate utilisation but requires external energy deficit. Doesn't address NAD+ depletion that limits mitochondrial function over time
SR9009 (Stenabolic)	REV-ERB agonist → circadian metabolism regulation	Indirect via mitochondrial biogenesis	5–12% increase in resting energy expenditure	Low. Short half-life limits sustained effect	Mechanism is sound but dosing practicality is challenging. Oral bioavailability is poor, requiring frequent redosing or alternative delivery
Yohimbine HCL	Alpha-2 adrenergic antagonist → lipolysis in stubborn fat depots	No NAD+ effect	Regional fat mobilisation in alpha-2 receptor-dense areas (lower abdomen, hips)	Minimal. Works acutely but doesn't prevent downregulation	Useful for acute fat release but doesn't address systemic metabolic adaptation. Best as a targeted adjunct, not a primary metabolic intervention

What If: 5-Amino-1MQ for Cutting Cycle Scenarios

What If You Start 5-Amino-1MQ Mid-Cut After Metabolic Slowdown Has Already Occurred?

It still works, but you're playing catch-up. NAD+ restoration begins within 48–72 hours, but the downstream effects. Upregulated mitochondrial enzyme expression, restored AMPK activity. Take 7–14 days to fully manifest. If you're already 8–10 weeks into a deficit with suppressed thyroid hormones and reduced NEAT, introducing 5-amino-1MQ will gradually restore fat oxidation capacity but won't reverse leptin suppression or restore output immediately. Pair it with a structured refeed (2–3 days at maintenance calories with elevated carbohydrate intake) to acutely restore leptin and thyroid signalling while the NNMT inhibition rebuilds metabolic machinery in parallel.

What If You Stack 5-Amino-1MQ with GLP-1 Receptor Agonists During a Cut?

The mechanisms are complementary but the appetite suppression from GLP-1 agonists (semaglutide, tirzepatide) can make it difficult to maintain adequate protein intake. Which is critical during cutting cycles to preserve lean mass. GLP-1 agonists slow gastric emptying and suppress ghrelin signalling, reducing hunger acutely. 5-amino-1MQ doesn't affect appetite directly but increases the rate at which stored fat is oxidised for energy. The combination allows for a larger caloric deficit without triggering the metabolic adaptation that would normally occur, but protein intake must be monitored closely. Aim for 2.0–2.4g/kg to prevent muscle catabolism when appetite is blunted.

What If NAD+ Precursors Like NMN or NR Would Be Simpler Than Using 5-Amino-1MQ?

NAD+ precursors (nicotinamide mononucleotide, nicotinamide riboside) increase NAD+ availability by providing substrate for synthesis. But they don't address the enzymatic bottleneck. During prolonged dieting, NNMT expression increases 2–3× baseline, actively converting incoming nicotinamide into N1-methylnicotinamide faster than you can supplement it. You're pouring water into a bucket with a growing hole. 5-amino-1MQ plugs the hole by inhibiting the enzyme itself, making endogenous NAD+ synthesis more efficient. If you're already supplementing NMN or NR and not seeing metabolic effects during a cut, elevated NNMT activity is likely the limiting factor. Adding NNMT inhibition makes the precursors work.

The Unflinching Truth About 5-Amino-1MQ for Cutting Cycles

Here's the honest answer: 5-amino-1MQ addresses a real, measurable metabolic problem during sustained caloric restriction. NNMT-driven NAD+ depletion is not speculative, it's documented across multiple research models. But it doesn't override thermodynamics. If you're not in a caloric deficit, restoring NAD+ availability won't create fat loss on its own. The compound works by preventing the metabolic slowdown that typically forces you to drop calories lower and lower as a cut progresses. It keeps your mitochondria efficient so that a 500-calorie deficit in week 10 still produces the same rate of fat loss as it did in week 2. That's the value: sustained fat oxidation without the compounding adaptation that makes the final weeks of a cut brutal.

This isn't a miracle compound. It's a targeted intervention for a specific enzymatic problem. If your deficit is inconsistent, your protein intake is suboptimal, or your training volume drops because you're undersleeping and overreaching, 5-amino-1MQ won't fix those issues. What it will do is preserve the metabolic machinery that allows a well-structured cutting protocol to work for 12–16 weeks instead of stalling at week 8.

Stacking 5-Amino-1MQ with Other Metabolic Research Tools

The NNMT inhibition mechanism opens pathways that other compounds can exploit more effectively. L-carnitine (2–3g daily) transports long-chain fatty acids into mitochondria for oxidation. When 5-amino-1MQ increases mitochondrial density and NAD+-dependent enzyme activity, carnitine supplementation amplifies the rate at which liberated fatty acids are actually burned rather than re-esterified back into triglycerides. Forskolin (250–500mg standardised to 10% forskolin content) activates adenylyl cyclase, increasing cAMP levels that trigger hormone-sensitive lipase (HSL). The enzyme that releases fatty acids from adipocytes. NNMT inhibition ensures those released fatty acids are oxidised efficiently rather than being repackaged due to impaired mitochondrial function.

Caffeine and yohimbine are frequently used during cuts for acute lipolysis, but their effectiveness depends on downstream oxidative capacity. If NAD+ is depleted and mitochondrial function is suppressed, mobilising more fatty acids into circulation doesn't increase fat loss. It just elevates circulating triglycerides temporarily. Restoring NAD+ availability with 5-amino-1MQ for cutting cycle protocols ensures that lipolytic agents produce actual fat oxidation rather than transient mobilisation. Our team has observed that athletes using NNMT inhibitors report sustained energy levels and preserved training performance during deficit phases. Likely due to improved mitochondrial ATP production as NAD+ availability remains high.

Explore structured metabolic research stacks designed for cutting phases, including NAD+ optimisation tools and mitochondrial support compounds, through our Fat Loss Metabolic Health Bundle and Body Recomp Bundle, formulated to address the exact enzymatic and hormonal shifts that limit fat loss during prolonged restriction.

The challenge with 5-amino-1MQ isn't the mechanism. It's the execution. Subcutaneous administration requires precision, reconstitution of lyophilised peptides demands sterile technique, and dosing consistency matters when you're targeting an enzyme with a narrow inhibition curve. Most athletes underestimate the difference between a protocol executed at 80% compliance and one executed at 95%. The metabolic outcomes diverge sharply after week 4. If you're considering 5-amino-1MQ for a cutting cycle, treat it like periodised training: plan the entire intervention upfront, structure refeeds deliberately, and monitor bodyweight, strength metrics, and subjective energy levels weekly to catch adaptation before it compounds.

All compounds discussed on this page are sold for research use only and are not for human consumption.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

5-amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), the enzyme that depletes NAD+ during caloric restriction, addressing the root cause of metabolic slowdown rather than acutely stimulating thermogenesis. Traditional fat burners like caffeine or ephedrine increase energy expenditure through beta-adrenergic receptor activation — which works acutely but doesn't prevent the enzymatic adaptation that suppresses fat oxidation after 6–8 weeks of dieting. NNMT inhibition preserves NAD+ levels in adipose tissue by 40–60%, maintaining mitochondrial function and AMPK signalling throughout the deficit phase so that fat oxidation rates remain elevated even as the body attempts to conserve energy.

Yes, by targeting the NNMT-NAD+ axis that drives diet-induced metabolic slowdown. Research published in Cell Metabolism showed that NNMT inhibition in mice on prolonged caloric restriction maintained energy expenditure at baseline levels and prevented the typical 20–30% decline in resting metabolic rate that occurs during extended deficits. The mechanism works because NAD+ preservation keeps SIRT1 and AMPK pathways active — these enzymes regulate mitochondrial biogenesis and fat oxidation, so maintaining their activity during a cut prevents the shift toward energy conservation that normally forces you to drop calories progressively lower as the diet continues.

Preclinical research used doses of 25–50mg per kilogram body weight in rodent models, which translates to approximately 4–8mg/kg in human-equivalent dosing using FDA allometric scaling. For a 90kg individual, this suggests a range of 360–720mg daily, though most anecdotal reports from researchers working with 5-amino-1MQ describe subcutaneous administration of 50–100mg daily. No formal human clinical trials have established optimal dosing as of 2026, so current protocols are derived from animal research and researcher case reports rather than controlled human studies.

NAD+ levels in adipose tissue begin to restore within 48–72 hours of NNMT inhibition, but the downstream metabolic effects take 7–14 days to fully manifest. This includes upregulation of mitochondrial enzyme expression, increased PGC-1α activity driving mitochondrial biogenesis, and elevated AMPK signalling shifting cells toward fat oxidation. Starting 5-amino-1MQ 1–2 weeks before entering a caloric deficit allows the metabolic machinery to be in place before restriction begins, maximising the compound's ability to prevent adaptation rather than having to reverse it mid-cut.

NNMT activity returns to baseline within 3–5 days of discontinuing the inhibitor, and NAD+ levels will gradually decline if the caloric deficit continues. This doesn't cause an acute metabolic crash, but the protective effect against adaptation is lost — meaning fat oxidation rates will decrease and energy expenditure will start to decline as NNMT upregulation resumes. If you need to discontinue mid-cut, pair the transition with a structured refeed (2–3 days at maintenance calories) to acutely restore leptin and thyroid signalling while NNMT activity re-establishes, minimising the immediate drop in metabolic rate.

Yes — the NNMT inhibition mechanism is complementary to compounds that work through different pathways. Stacking with L-carnitine (2–3g daily) enhances fatty acid transport into mitochondria, amplifying the oxidative capacity 5-amino-1MQ unlocks by restoring NAD+. Combining with GLP-1 receptor agonists (semaglutide, tirzepatide) creates a larger caloric deficit through appetite suppression while NNMT inhibition prevents the metabolic slowdown that would normally accompany such a deficit. Forskolin and yohimbine increase acute lipolysis, releasing fatty acids from adipocytes — but their effectiveness depends on downstream oxidative capacity, which 5-amino-1MQ preserves by maintaining mitochondrial NAD+ levels.

No long-term human safety data exists as of 2026 — 5-amino-1MQ remains a research compound without FDA approval for human use. Preclinical studies in rodent models showed no acute toxicity at doses up to 50mg/kg over 10-week periods, but chronic NNMT inhibition effects on methylation pathways, liver function, and other NAD+-dependent processes in humans have not been formally studied. Anyone considering extended use during cutting cycles should monitor liver enzymes (AST, ALT), lipid panels, and methylation markers (homocysteine levels) regularly and work under medical supervision.

NAD+ precursors provide substrate for synthesis but don't address the enzymatic bottleneck. During prolonged caloric restriction, NNMT expression increases 2–3× baseline levels, actively converting incoming nicotinamide into N1-methylnicotinamide faster than supplementation can restore NAD+ pools. This is why many athletes supplementing high-dose NMN (500–1000mg daily) still experience metabolic slowdown after week 6–8 of a cut — the enzyme activity outpaces the substrate supply. 5-amino-1MQ inhibits NNMT directly, preventing the conversion and making endogenous NAD+ synthesis more efficient, which is why it produces measurable metabolic effects where precursor supplementation alone often does not.

Indirectly, by maintaining energy expenditure and fat oxidation rates, which allows for a smaller caloric deficit to achieve the same rate of fat loss. Muscle catabolism during cuts is driven primarily by insufficient protein intake and excessive energy deficits that force the body to break down lean tissue for gluconeogenesis. By preventing the metabolic adaptation that typically requires progressively lower calorie intakes as a cut extends, 5-amino-1MQ allows athletes to maintain higher protein intakes (2.0–2.4g/kg) and smaller deficits while still losing fat, reducing the stimulus for muscle breakdown. The compound doesn't have direct anti-catabolic properties like mTOR activation — its muscle-sparing effect comes from optimising the metabolic context in which the deficit occurs.

Starting too late in the cut — NAD+ restoration and downstream metabolic effects take 7–14 days to fully manifest, so beginning after metabolic slowdown has already occurred means playing catch-up rather than preventing adaptation. Inconsistent dosing due to poor reconstitution technique or irregular administration schedules — NNMT inhibition requires sustained plasma levels to maintain effect. Expecting 5-amino-1MQ to override poor deficit structure — the compound prevents metabolic adaptation, but you still need to be in a caloric deficit with adequate protein intake and progressive training stimulus for fat loss to occur. Failing to monitor energy levels, strength metrics, and bodyweight trends weekly to confirm the compound is working as intended and catch any signs of overreaching or inadequate recovery.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA